PCN71 COST-EFFECTIVENESS (CE) ANALYSIS OF ERBB2-TARGETED THERAPIES IN WOMEN WITH TRASTUZUMAB (TZ)-REFRACTORY ERBB2 METASTATIC BREAST CANCER (MBC) AND LIMITED EXPOSURE TO PRIOR CHEMOTHERAPY (CT)
May 1, 2009, 00:00 AM
10.1016/S1098-3015(10)73308-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)73308-8/fulltext
Section Title :
Section Order :
730
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73308-8&doi=10.1016/S1098-3015(10)73308-8